Resveratrol mediated modulation of sirt-1/Runx2 promotes osteogenic differentiation of mesenchymal stem cells: Potential role of Runx2 deacetylation

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Shakibaei, Mehdi ^a   Shayan, Parviz ^b   Busch, Franziska ^a   Aldinger, Constance ^a   Buhrmann, Constanze ^a   Lueders, Cora ^c   Mobasheri, Ali ^d  

^a UNIVERSITY OF MUNICH   (Germany)

^b Investigating Institute of Molecular Biological System Transfer   (Iran)

^c DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BETA ACTIN; COLLAGEN TYPE 1; NICOTINAMIDE; NUCLEAR RECEPTOR COREPRESSOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RESVERATROL; SIRTUIN 1; TRANSCRIPTION FACTOR RUNX2; NCOR1 PROTEIN, HUMAN; NONSTEROID ANTIINFLAMMATORY AGENT; RECEPTOR INTERACTING PROTEIN 140; SIRT1 PROTEIN, MOUSE; STILBENE DERIVATIVE;

ADIPOCYTE; ADIPOGENESIS; ADIPOSE TISSUE; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE DEVELOPMENT; CELL DIFFERENTIATION; CELL LINE; CELL VACUOLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DEACETYLATION; DOG; DOWN REGULATION; ELECTRON MICROSCOPY; ENZYME REPRESSION; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; IMMUNOPRECIPITATION; MESENCHYMAL STEM CELL; MITOCHONDRION; MONOLAYER CULTURE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOBLAST; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; ROUGH ENDOPLASMIC RETICULUM; SIGNAL TRANSDUCTION; UPREGULATION; ACETYLATION; ANIMAL; CHEMISTRY; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; MOUSE;

ACETYLATION; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL DIFFERENTIATION; CORE BINDING FACTOR ALPHA 1 SUBUNIT; DOWN-REGULATION; MESENCHYMAL STEM CELLS; MICE; NIACINAMIDE; NUCLEAR RECEPTOR CO-REPRESSOR 1; OLIGONUCLEOTIDES, ANTISENSE; OSTEOGENESIS; PPAR GAMMA; SIRTUIN 1; STILBENES;

EID: 84859974018     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035712     Document Type: Article

References (50)

1. Baksh D, Song L, Tuan RS, (2004) Adult mesenchymal stem cells: characterization, differentiation, and application in cell and gene therapy. J Cell Mol Med 8: 301-316.
2. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, et al. (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284: 143-147.
3. Lee OK, Kuo TK, Chen WM, Lee KD, Hsieh SL, et al. (2004) Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood 103: 1669-1675.
4. Burkhardt R, Kettner G, Bohm W, Schmidmeier M, Schlag R, et al. (1987) Changes in trabecular bone, hematopoiesis and bone marrow vessels in aplastic anemia, primary osteoporosis, and old age: a comparative histomorphometric study. Bone 8: 157-164.
5. Kanis JA, Melton LJ, 3rd, Christiansen C, Johnston CC, Khaltaev N, (1994) The diagnosis of osteoporosis. J Bone Miner Res 9: 1137-1141.
6. Blank RD, Bockman RS, (1999) A review of clinical trials of therapies for osteoporosis using fracture as an end point. J Clin Densitom 2: 435-452.
7. Vihtamaki T, Savilahti R, Tuimala R, (1999) Why do postmenopausal women discontinue hormone replacement therapy? Maturitas 33: 99-105.
8. Baolin L, Inami Y, Tanaka H, Inagaki N, Iinuma M, et al. (2004) Resveratrol inhibits the release of mediators from bone marrow-derived mouse mast cells in vitro. Planta Med 70: 305-309.
9. Bowers JL, Tyulmenkov VV, Jernigan SC, Klinge CM, (2000) Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 141: 3657-3667.
10. Mizutani K, Ikeda K, Kawai Y, Yamori Y, (1998) Resveratrol stimulates the proliferation and differentiation of osteoblastic MC3T3-E1 cells. Biochem Biophys Res Commun 253: 859-863.
11. Cao Z, Li Y, (2004) Potent induction of cellular antioxidants and phase 2 enzymes by resveratrol in cardiomyocytes: protection against oxidative and electrophilic injury. Eur J Pharmacol 489: 39-48.
12. Savouret JF, Quesne M, (2002) Resveratrol and cancer: a review. Biomed Pharmacother 56: 84-87.
13. Song LH, Pan W, Yu YH, Quarles LD, Zhou HH, et al. (2006) Resveratrol prevents CsA inhibition of proliferation and osteoblastic differentiation of mouse bone marrow-derived mesenchymal stem cells through an ER/NO/cGMP pathway. Toxicol In Vitro 20: 915-922.
14. Tseng PC, Hou SM, Chen RJ, Peng HW, Hsieh CF, et al. (2011) Resveratrol promotes osteogenesis of human mesenchymal stem cells by upregulating RUNX2 gene expression via the SIRT1/FOXO3A axis. J Bone Miner Res 26: 2552-2563.
15. Haigis MC, Guarente LP, (2006) Mammalian sirtuins-emerging roles in physiology, aging, and calorie restriction. Genes Dev 20: 2913-2921.
16. Imai S, Armstrong CM, Kaeberlein M, Guarente L, (2000) Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403: 795-800.
17. Sherman JM, Stone EM, Freeman-Cook LL, Brachmann CB, Boeke JD, et al. (1999) The conserved core of a human SIR2 homologue functions in yeast silencing. Mol Biol Cell 10: 3045-3059.
18. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, et al. (2003) Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425: 191-196.
19. Backesjo CM, Li Y, Lindgren U, Haldosen LA, (2006) Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells. J Bone Miner Res 21: 993-1002.
20. Semple RK, Chatterjee VK, O'Rahilly S, (2006) PPAR gamma and human metabolic disease. J Clin Invest 116: 581-589.
21. Michalik L, Wahli W, (2006) Involvement of PPAR nuclear receptors in tissue injury and wound repair. J Clin Invest 116: 598-606.
22. Nuttall ME, Gimble JM, (2004) Controlling the balance between osteoblastogenesis and adipogenesis and the consequent therapeutic implications. Curr Opin Pharmacol 4: 290-294.
23. Rosen ED, Spiegelman BM, (2001) PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 276: 37731-37734.
24. Nuttall ME, Patton AJ, Olivera DL, Nadeau DP, Gowen M, (1998) Human trabecular bone cells are able to express both osteoblastic and adipocytic phenotype: implications for osteopenic disorders. J Bone Miner Res 13: 371-382.
25. Chen JD, Evans RM, (1995) A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 377: 454-457.
26. Shibata H, Nawaz Z, Tsai SY, O'Malley BW, Tsai MJ, (1997) Gene silencing by chicken ovalbumin upstream promoter-transcription factor I (COUP-TFI) is mediated by transcriptional corepressors, nuclear receptor-corepressor (N-CoR) and silencing mediator for retinoic acid receptor and thyroid hormone receptor (SMRT). Mol Endocrinol 11: 714-724.
27. Ducy P, (2000) Cbfa1: a molecular switch in osteoblast biology. Dev Dyn 219: 461-471.
28. Kanno T, Takahashi T, Tsujisawa T, Ariyoshi W, Nishihara T, (2007) Mechanical stress-mediated Runx2 activation is dependent on Ras/ERK1/2 MAPK signaling in osteoblasts. J Cell Biochem 101: 1266-1277.
29. Buhrmann C, Mobasheri A, Matis U, Shakibaei M, (2010) Curcumin mediated suppression of nuclear factor-kappaB promotes chondrogenic differentiation of mesenchymal stem cells in a high-density co-culture microenvironment. Arthritis Res Ther 12: R127.
30. Shakibaei M, Buhrmann C, Mobasheri A, (2011) Resveratrol-mediated SIRT-1 interactions with p300 modulate receptor activator of NF-kappaB ligand (RANKL) activation of NF-kappaB signaling and inhibit osteoclastogenesis in bone-derived cells. J Biol Chem 286: 11492-11505.
31. Fatokun AA, Stone TW, Smith RA, (2006) Hydrogen peroxide-induced oxidative stress in MC3T3-E1 cells: The effects of glutamate and protection by purines. Bone 39: 542-551.
32. Shakibaei M, (1998) Inhibition of chondrogenesis by integrin antibody in vitro. Exp Cell Res 240: 95-106.
33. Csaki C, Matis U, Mobasheri A, Ye H, Shakibaei M, (2007) Chondrogenesis, osteogenesis and adipogenesis of canine mesenchymal stem cells: a biochemical, morphological and ultrastructural study. Histochem Cell Biol 128: 507-520.
34. Chalk AM, Sonnhammer EL, (2002) Computational antisense oligo prediction with a neural network model. Bioinformatics 18: 1567-1575.
35. Shakibaei M, De Souza P, Merker HJ, (1997) Integrin expression and collagen type II implicated in maintenance of chondrocyte shape in monolayer culture: an immunomorphological study. Cell Biol Int 21: 115-125.
36. Shakibaei M, John T, Schulze-Tanzil G, Lehmann I, Mobasheri A, (2007) Suppression of NF-kappaB activation by curcumin leads to inhibition of expression of cyclo-oxygenase-2 and matrix metalloproteinase-9 in human articular chondrocytes: Implications for the treatment of osteoarthritis. Biochem Pharmacol 73: 1434-1445.
37. Shakibaei M, John T, De Souza P, Rahmanzadeh R, Merker HJ, (1999) Signal transduction by beta1 integrin receptors in human chondrocytes in vitro: collaboration with the insulin-like growth factor-I receptor. Biochem J 342 Pt 3: 615-623.
38. Shakibaei M, Csaki C, Nebrich S, Mobasheri A, (2008) Resveratrol suppresses interleukin-1beta-induced inflammatory signaling and apoptosis in human articular chondrocytes: potential for use as a novel nutraceutical for the treatment of osteoarthritis. Biochem Pharmacol 76: 1426-1439.
39. Picard F, Kurtev M, Chung N, Topark-Ngarm A, Senawong T, et al. (2004) Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 429: 771-776.
40. Lian JB, Javed A, Zaidi SK, Lengner C, Montecino M, et al. (2004) Regulatory controls for osteoblast growth and differentiation: role of Runx/Cbfa/AML factors. Crit Rev Eukaryot Gene Expr 14: 1-41.
41. Quarles LD, Yohay DA, Lever LW, Caton R, Wenstrup RJ, (1992) Distinct proliferative and differentiated stages of murine MC3T3-E1 cells in culture: an in vitro model of osteoblast development. J Bone Miner Res 7: 683-692.
42. Guenther MG, Barak O, Lazar MA, (2001) The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3. Mol Cell Biol 21: 6091-6101.
43. Gehm BD, McAndrews JM, Chien PY, Jameson JL, (1997) Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci U S A 94: 14138-14143.
44. Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, et al. (2007) Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 109: 2293-2302.
45. Huang Z, Wang C, Wei L, Wang J, Fan Y, et al. (2008) Resveratrol inhibits EMMPRIN expression via P38 and ERK1/2 pathways in PMA-induced THP-1 cells. Biochem Biophys Res Commun 374: 517-521.
46. Kundu JK, Shin YK, Kim SH, Surh YJ, (2006) Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF-kappaB in mouse skin by blocking IkappaB kinase activity. Carcinogenesis 27: 1465-1474.
47. Venkatesan B, Ghosh-Choudhury N, Das F, Mahimainathan L, Kamat A, et al. (2008) Resveratrol inhibits PDGF receptor mitogenic signaling in mesangial cells: role of PTP1B. FASEB J 22: 3469-3482.
48. Chen L, Fischle W, Verdin E, Greene WC, (2001) Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science 293: 1653-1657.
49. Gu W, Roeder RG, (1997) Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90: 595-606.
50. Martinez-Balbas MA, Bauer UM, Nielsen SJ, Brehm A, Kouzarides T, (2000) Regulation of E2F1 activity by acetylation. EMBO J 19: 662-671.